N30 Pharmaceuticals becomes Nivalis Therapeutics

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).

The new corporate name, Nivalis Therapeutics, originated from one of the Company's own scientists, and is derived from the Latin term for 'of snow.' Just as each snowflake is unique, so too is each person with CF. With more than 1,800 known mutations of the gene responsible for CF, treating the disease requires solutions as unique as snowflakes.

"The organization has transitioned from an early-stage Company focused on research to a clinical-stage Company that is now focused on translating precision-based scientific discoveries into patient benefit," said Jon Congleton, president and chief executive officer of Nivalis Therapeutics. "As part of this evolution, we believe that it is important for the Company name to better articulate the commitment, passion and energy that we are bringing to the cystic fibrosis community as we strive to develop and bring to market innovative solutions that may improve and extend the lives of people managing this disease."